Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.
| Author | |
| Abstract |
:
At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported. |
| Year of Publication |
:
2021
|
| Journal |
:
The New England journal of medicine
|
| Volume |
:
385
|
| Issue |
:
19
|
| Number of Pages |
:
1774-1785
|
| Date Published |
:
2021
|
| ISSN Number |
:
0028-4793
|
| URL |
:
https://www.nejm.org/doi/10.1056/NEJMoa2113017?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed
|
| DOI |
:
10.1056/NEJMoa2113017
|
| Short Title |
:
N Engl J Med
|
| Download citation |
